New England Journal of Medicine· 2013Q1· Clinical trial

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn et al.

2,259citations
Q1SCImago
2013year

Short summary

Ibrutinib, a novel oral BTK inhibitor, demonstrated a 71% overall response rate in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), regardless of high-risk genetic factors.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Genetics

GeneticsMedicine